Literature DB >> 33294925

In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii.

A R Noel1, M Attwood1, K E Bowker1, A P MacGowan1.   

Abstract

BACKGROUND: The pharmacodynamics of omadacycline have been extensively studied against Gram-positive pathogens but less information is available for Gram-negative pathogens. We describe the pre-clinical pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii.
METHODS: An in vitro dilutional pharmacokinetic model was used. Exposure experiments with fAUC/MIC ratios ranging from 0 to 1200 were performed using five strains of E. coli and five strains of A. baumannii. Reduction in bacterial load and changes in population profiles were measured.
RESULTS: The fAUC/MIC targets against E. coli for 24 h static and -1 log reduction in load were 25.3 ± 17.2 and 42.7 ± 32.5, respectively. For A. baumannii the fAUC/MIC for 24 h static effect was 108.1 ± 38.6. Changes in population profiles were observed for E. coli at fAUC/MIC ratios of ≤200 and for A. baumannii up to 1200. MICs were increased 2-32 fold.
CONCLUSIONS: fAUC/MIC targets for A. baumannii are greater than for E.coli and changes in population profiles more likely. E. coli fAUC/MIC targets align with in vivo data and will be useful in determining omadacycline dosing for this pathogen.
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33294925     DOI: 10.1093/jac/dkaa508

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects.

Authors:  Haijing Yang; Zhiwei Huang; Yuancheng Chen; Yusong Zhu; Guoying Cao; Jingjing Wang; Yan Guo; Jicheng Yu; Jufang Wu; Lichuan Liu; Jun Deng; Jing Liu; Harald Reinhart; Jing Zhang; Xiaojie Wu
Journal:  Front Pharmacol       Date:  2022-04-21       Impact factor: 5.988

2.  Potency of Omadacycline against Mycobacteroides abscessus Clinical Isolates In Vitro and in a Mouse Model of Pulmonary Infection.

Authors:  Emily C Maggioncalda; Elizabeth Story-Roller; Danielle A Nicklas; Benjamin Eichelman; Chavis Tabor; Alisa W Serio; Tiffany R Keepers; Surya Chitra; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2021-10-18       Impact factor: 5.191

3.  Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens.

Authors:  Taylor Morrisette; Sara Alosaimy; Abdalhamid M Lagnf; Jeremy J Frens; Andrew J Webb; Michael P Veve; Ryan Stevens; Jeannette Bouchard; Tristan W Gore; Iman Ansari; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2022-05-14

4.  Activity of Omadacycline Alone and in Combination against Carbapenem-Nonsusceptible Acinetobacter baumannii with Varying Minocycline Susceptibility.

Authors:  Taylor Abbey; Alesia Vialichka; Michele Jurkovic; Mark Biagi; Eric Wenzler
Journal:  Microbiol Spectr       Date:  2022-06-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.